PUBLISHER: IMARC | PRODUCT CODE: 1467656
PUBLISHER: IMARC | PRODUCT CODE: 1467656
The global recombinant protein market size reached US$ 1.90 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.58 Billion by 2032, exhibiting a growth rate (CAGR) of 10.1% during 2024-2032.
A recombinant protein refers to a modified or altered protein that is encoded by recombinant DNA. The recombinant DNA molecule consists of a plasmid in which the genes for a target protein are cloned. It is produced either by molecular cloning or polymerase chain reaction (PCR). Some of the common product variants include kinase proteins, human insulin, structural proteins, adhesion molecules and receptors, immune response proteins, etc. Recombinant protein is primarily utilized in the development of novel therapies for chronic and rare diseases. It finds widespread adoption in numerous biopharmaceutical companies, academic and research institutes, contract research organizations, etc.
The elevating prevalence of several chronic diseases along with the increasing demand for novel treatment options is primarily driving the global recombinant protein market. In addition to this, the rising investments in the field of protein engineering and the improving focus on protein-based drug development are further augmenting the market growth. Moreover, numerous government bodies are funding R&D activities for the introduction of advanced techniques in proteomics and genomics, which are significantly impacting the global market for recombinant protein. Besides this, the advent of recombinant protein expression technology has led to the development of high-quality autoantigens that are widely used in immunotherapy procedures. Additionally, the growing requirement for recombinant proteins for accurate measurement of biomarkers in the field of drug discovery is also creating a positive outlook for the global market. Apart from this, the rising penetration of latest molecular biology approaches for biopharming to reduce proteolysis of recombinant proteins or prevent the partial or total loss of glycosylation is expected to bolster the global recombinant protein market over the forecast period.
IMARC Group provides an analysis of the key trends in each sub-segment of the global recombinant protein market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and end user.
Antibodies
Hormones
Growth Factors
Cytokines
Others
Drug Discovery and Development
Academic Research
Biotechnology Research
Biopharmaceutical Production
Others
Pharmaceutical and Biopharmaceutical Companies
Biotechnology Companies
Academic and Research Institutes
Contract Research Organization
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abcam plc, Amgen Inc., Bio-RAD Laboratories Inc., Bio-Techne Corporation, Bps Bioscience Inc., Enzo Biochem Inc., Genscript Biotech Corporation, Merck KGaA, Novo Nordisk A/S, ProSpec-Tany TechnoGene Ltd, Sanofi S.A. and Thermo Fisher Scientific.